lixivaptan has been researched along with arginine vasopressin in 23 studies
Studies (lixivaptan) | Trials (lixivaptan) | Recent Studies (post-2010) (lixivaptan) | Studies (arginine vasopressin) | Trials (arginine vasopressin) | Recent Studies (post-2010) (arginine vasopressin) |
---|---|---|---|---|---|
80 | 10 | 26 | 12,278 | 422 | 1,212 |
Protein | Taxonomy | lixivaptan (IC50) | arginine vasopressin (IC50) |
---|---|---|---|
Vasopressin V2 receptor | Homo sapiens (human) | 0.242 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (13.04) | 18.2507 |
2000's | 15 (65.22) | 29.6817 |
2010's | 5 (21.74) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Double-Cazanave, E; Garcia, C; Guillon, G; Maffrand, JP; Pascal, M; Raufaste, D; Serradeil-Le Gal, C | 1 |
Albright, JD; Bailey, T; Chan, PS; Coupet, J; Delos Santos, EG; Dusza, JP; Mazandarani, H; Reich, MF; Ru, X; Sum, FW; Venkatesan, AM | 1 |
Albright, JD; Bailey, T; Cervoni, P; Chan, PS; Coupet, J; Dusza, JP; Hartupee, D; Lai, F; Lock, TY; Mazandarani, H; Ning, X; Ochalski, L; Park, HC; Ru, X; Shepherd, C; Spinelli, W; Tanikella, T; Taylor, JR | 1 |
Abraham, WT; Lieming, X; Martin, PY; Ohara, M; Olson, BR; Oren, RM; Schrier, RW | 1 |
Angers, S; Arthus, MF; Bernier, V; Bichet, DG; Bouvier, M; Laperrière, A; Lonergan, M; Morello, JP; Morin, D; Petäjä-Repo, U; Salahpour, A | 1 |
Thibonnier, M | 1 |
Pham, PC; Pham, PM; Pham, PT | 1 |
Verbalis, JG | 1 |
Omland, T; Solberg, OG | 1 |
Ali, F; Ghali, JK; Guglin, M; Vaitkevicius, P | 1 |
Balk, RA; Patel, GP | 1 |
Kumar, S; Mather, PJ; Rubin, S; Whellan, DJ | 1 |
Haskal, R | 1 |
Schweiger, TA; Zdanowicz, MM | 1 |
Farmakis, D; Filippatos, G; Gheorghiade, M; Kremastinos, DT | 1 |
Boerrigter, G; Burnett, JC; Costello-Boerrigter, LC | 1 |
Kumar, SK; Mather, PJ | 1 |
Goldsmith, SR | 1 |
Ghali, JK; Tam, SW | 1 |
Daifallah, S; Farah, JO; Ghali, JK; Zmily, HD | 1 |
Cantillo, DS; Comín Colet, J; Robledo, GG | 1 |
Daifallah, S; Ghali, JK; Khan, NS; Zmily, HD | 1 |
Iwao, H; Izumi, Y; Miura, K | 1 |
19 review(s) available for lixivaptan and arginine vasopressin
Article | Year |
---|---|
VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Blood Pressure; Cyclic AMP; Dogs; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney; Pyrroles; Receptors, Vasopressin | 1998 |
Vasopressin receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2003 |
Vasopressin excess and hyponatremia.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
AVP receptor antagonists as aquaretics: review and assessment of clinical data.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan; Water-Electrolyte Balance | 2006 |
[Arginine vasopressin antagonism--new treatment option in chronic heart failure].
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Nephrons; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; Treatment Outcome; Vasoconstrictor Agents | 2007 |
Therapeutic potential of vasopressin receptor antagonists.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Liver Cirrhosis; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2007 |
Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Critical Illness; Humans; Hyponatremia; Inpatients; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Tolvaptan | 2007 |
Hyponatremia and vasopressin antagonism in congestive heart failure.
Topics: Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hyponatremia; Models, Biological; Pyrroles; Registries; Renin-Angiotensin System; Sodium; Tolvaptan; Treatment Outcome; Vasopressins | 2007 |
Current issues for nurse practitioners: Hyponatremia.
Topics: Aged; Algorithms; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Causality; Decision Trees; Diagnosis, Differential; Early Diagnosis; Female; Homeostasis; Humans; Hyponatremia; Nurse Practitioners; Nurse's Role; Nursing Assessment; Patient Selection; Primary Health Care; Pyrroles; Tolvaptan; Water-Electrolyte Balance | 2007 |
Vasopressin-receptor antagonists in heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Cardiovascular Agents; Chronic Disease; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Tolvaptan | 2008 |
Vasopressin and vasopressin antagonists in heart failure and hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart Failure; Humans; Hyponatremia; Infusions, Intravenous; Male; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Risk Assessment; Survival Rate; Tolvaptan; Water-Electrolyte Imbalance | 2008 |
Pharmacology of vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Benzodiazepines; Heart Failure; Humans; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2009 |
AVP receptor antagonists in patients with CHF.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Pyrroles; Receptors, Vasopressin; Sodium | 2009 |
Treatment options for hyponatremia in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Benzazepines; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Pyrroles; Sodium Potassium Chloride Symporter Inhibitors; Tolvaptan; Treatment Outcome | 2009 |
The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists.
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Blood Pressure; Blood Volume; Female; Heart Failure; Humans; Hypertension; Hyponatremia; Male; Prevalence; Prognosis; Pyrroles; Receptors, Vasopressin; Tolvaptan; United States; Water-Electrolyte Balance | 2010 |
Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Clinical Trials as Topic; Dogs; Heart Failure; Humans; Hyponatremia; Pyrroles; Rats | 2010 |
[Hyponatremia in heart failure: physiopathology and pharmacological approach].
Topics: Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Brain Edema; Demyelinating Diseases; Diuresis; Diuretics; Double-Blind Method; Heart Failure; Humans; Hyponatremia; Kidney; Multicenter Studies as Topic; Natriuresis; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Saline Solution, Hypertonic; Sympathetic Nervous System; Tolvaptan | 2010 |
The potential role for lixivaptan in heart failure and in hyponatremia.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Heart Failure; Humans; Hyponatremia; Plasma Volume; Pyrroles | 2011 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
2 trial(s) available for lixivaptan and arginine vasopressin
Article | Year |
---|---|
5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.
Topics: Administration, Oral; Animals; Arginine Vasopressin; Azepines; Benzamides; Blood Platelets; Body Water; Cell Line; Cell Membrane; Dogs; Fibroblasts; Humans; Kidney; Liver; Osmolar Concentration; Pyrroles; Rats; Receptors, Vasopressin; Sodium; Structure-Activity Relationship; Urine | 1998 |
Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure.
Topics: Administration, Oral; Aged; Aquaporin 2; Aquaporin 6; Aquaporins; Arginine Vasopressin; Azepines; Benzamides; Biomarkers; Blotting, Western; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Pyrroles; Reference Values; Sensitivity and Specificity | 1999 |
2 other study(ies) available for lixivaptan and arginine vasopressin
Article | Year |
---|---|
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Binding, Competitive; Cattle; CHO Cells; Cricetinae; Dogs; Haplorhini; Homeostasis; Humans; Kidney; Kinetics; Morpholines; Rabbits; Radioligand Assay; Rats; Spiro Compounds; Swine; Tritium; Vasopressins; Water-Electrolyte Balance | 2000 |
Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Azepines; Benzamides; Cell Line; Cell Membrane; COS Cells; Diabetes Insipidus, Nephrogenic; Flow Cytometry; Humans; Intracellular Fluid; Molecular Chaperones; Morpholines; Mutagenesis; Protein Folding; Pyrroles; Receptors, Vasopressin; Spiro Compounds | 2000 |